Infusion of PD1/PDL1 Inhibitor Via Hepatic Arterial Versus Vein for Immunotherapy of Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-01-02
Target enrollment:
Participant gender:
Summary
This trial was designed to investigate the survival outcomes, response rates, and safety of
patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by
hepatic artery versus vein infusion of PD1/PDL1 inhibitor.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University